A Phase 1 First-in-Human Open-label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation.

Study Overview

This research study is being done to test the effects of a new investigational drug therapy called AMG 510 which is being investigated for the treatment of advanced solid tumors with a specific KRAS mutation.

Study Description

This is a Phase 1 first in human, open-label study evaluating the safety, tolerability, pharmacokinetics, and Efficacy, of AMG 510 in Subjects with Advanced Solid Tumors with a Specific KRAS Mutation.

Additional Information

Participants will be compensated for their participation.


  • IRB Number: 1806140760 (20170543)
  • Research Study Identifier: TX9005
  • Principal Investigator: Greg Durm, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176